NCT06243393View on ClinicalTrials.gov

Sacituzumab Govitecan in Metastatic Colorectal Cancer

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 19, 2024

Primary Completion Date

August 1, 2028

Study Completion Date

February 1, 2029

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Sacituzumab Govitecan (SG)

Treatment with Sacituzumab Govitecan (SG)

DRUG

Physicians Choice (PhC).

Treatment according to oncologic guidelines.

Trial Locations (1)

69124

RECRUITING

University Hospital Heidelberg, Heidelberg

All Listed Sponsors
lead

University Hospital Heidelberg

OTHER